Bregal Milestone and Ridango Announce the Acquisition of uTrack Software Solutions
24.4.2025 15:00:00 CEST | Business Wire | Press release
Acquisition of the Irish software company to further enhance Ridango’s Automatic Vehicle Location offering
Bregal Milestone, a leading European software growth private equity firm, is pleased to share that, since announcing its strategic growth investment in Swedish global provider of mission-critical public transportation software Ridango AS (“Ridango”) last month, it has also agreed to acquire uTrack Software Solutions (“uTrack”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424607486/en/
Eamonn Hughes and Erki Lipre
Founded in 2011 by Eamonn Hughes and Conor Gildea, uTrack is a Dublin-headquartered software company providing a public transport data platform with a real-time analysis and predictive engine that feeds a suite of software services that annually supports nearly 3 billion passengers, over 5 million app users, 150,000+ drivers and 73,000+ vehicles.
uTrack‘s clients include some of the largest urban bus, intercity coach, and school transport providers across Ireland, the UK, and North America. The company’s suite of SaaS products: Origin, Unity & Rygo – enables operational excellence across a public transport business, mobile tools for a predominantly remote frontline workforce, and a transformative customer experience for passengers.
The acquisition of uTrack will aim to strengthen Ridango’s offerings by increasing capabilities for long-distance and school transport operators, expanding its presence in Western Europe and the US, and broadening its AVL product offering, particularly for the student and driver customer groups. The combined expertise of Ridango and uTrack will help further accelerate innovation with real-time connectivity, data-driven insights, and route optimisation, driving greater efficiency and improved experiences for both customers and operators.
Cyrus Shey, Managing Partner and Co-Founder at Bregal Milestone, commented, "We identified uTrack as a compelling strategic fit for Ridango given uTrack’s software platform, loyal and recurring customer base of market leading institutions, and complementary geographic presence, which made it a natural fit for the Ridango ecosystem. We’re excited to support this combination as it unlocks meaningful synergies and accelerates growth across both platforms."
Erki Lipre, Founder and CEO at Ridango, said, "The acquisition of uTrack represents a strategic leap forward for Ridango. By combining our strengths and complementary services, we will deepen Ridango’s AVL and analytics capabilities and significantly strengthen our position in key global markets. We are truly excited to welcome Eamonn, Conor, and the entire uTrack team to the Ridango family."
Co-founders of uTrack, Eamonn Hughes and Conor Gildea, added, "Joining forces with Ridango is an exciting milestone for uTrack. From day one, our mission has been to enhance the passenger and operator experience through technology. Partnering with Ridango allows us to accelerate that mission and scale our impact across Europe and North America while continuing to innovate with a shared vision for smarter, more sustainable transit."
The terms of the uTrack transaction were not disclosed and are conditional upon the completion of the Ridango transaction.
About Bregal Milestone
Bregal Milestone is a leading software private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading software companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €19 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2024. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Ridango
Ridango is the software operating system of choice for public transportation providers globally, specializing in automated fare collection (“AFC”), real-time passenger information systems, automatic vehicle location tracking (“AVL”), and mobility-as-a-service (“MaaS”) technology. The company partners with transport authorities and operators to enhance the efficiency, accessibility, and sustainability of public transit for customers and operators alike.
About uTrack
With strong expertise in inter-city travel, uTrack provides the digital software tools, innovation and expertise that enable public transport companies across the world to improve their businesses and deliver more targeted, reliable services that meet the demands of whole communities by growing passenger ridership, loyalty and satisfaction with the latest generation of real-time passenger information technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424607486/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom